Theriva™ Biologics (TOVX) addressed unusual trading activity on the NYSE American on Oct. 24, 2025, under NYSE Company Guide Section 401(d). The company found no need for corrective actions and identified no undisclosed developments to explain the market activity. However, on Oct. 13, 2025, Theriva™ announced expanded data from its VIRAGE trial on VCN-01 at ESMO 2025. Theriva™ Biologics is a clinical-stage company focused on cancer therapeutics, including VCN-01, SYN-004, and SYN-020, all aimed at treating cancer and related diseases in areas with high unmet needs. For more information, visit www.therivabio.com.

Read more at GlobeNewswire: Theriva Biologics Provides Response to Unusual Market